Neurology Specific Literature Search   
 
[home][thesaurus]
    

Enter your terms
above and click
the 'Search' button.
Showing articles 0 to 50 of 55 Next >>

Filter Applied: multiple sclerosis,treatment of (Click to remove)

Clinicopath Conf,Wegener's Granulomatosis with Pachymeningeal Granulomatous Inflammation, Case 9-1999
NEJM 340:945-953, , 1999

The Optic Nerve Should Graduate to Be the Fifth Lesion Site for the Diagnosis of Multiple Sclerosis
Neurol 102:e207919, Galetta,S. & Brownlee, W., 2024

Association of Initial Disease-Modifying Therapy with Later Conversion to Secondary Progressive Multiple Sclerosis
JAMA 32:175-187, Brown, J.W.L.,et al, 2019

Ocrelizumab versus Placebo in Primary Progressive Multiple Sclerosis
NEJM 376:209-220,280, Montalban, X.,et al, 2017

Clemastine Fumarate as a Remyelinating Therapy for Multiple Sclerosis (ReBUILD): A Randomised, Controlled, Double-Blind, Crossover Trial
Lancet 390:2481-2489, Green, A.J.,et al, 2017

Interferon beta for Secondary Progressive Multiple Sclerosis: A Systematic Review
JNNP 84:420-426, La Mantia, L.,et al, 2013

"Undiagnosing" Multiple Sclerosis
Neurol 78:1986-1991,1904, Solomon, A.J.,et al, 2012

Management and Outcome of CSF-JC Virus PCR-negative PML in a Natalizumab-treated Patient with MS
Neurol 77:2010-2016, Kuhle, J.,et al, 2011

Evidence Report: The Efficacy and Safety of Mitoxantrone (Novantrone) in the Treatment of Multiple Sclerosis: Report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology
Neurol 74:1463-1470, Marriott,J.J., et al, 2010

Tumefactive Demyelination: An Approach to Diagnosis and Management
JNNP 84:1047-1053, Hardy, T.A. & Chataway, J., 2009

Four New Cases of Therapy-Related Acute Promyelocytic Leukemia After Mitoxantrone
Neurol 71:457-458, Bosca,I.,et al., 2008

Monoclonal Antibody Therapies and Neurologic Disorders
Arch Neurol 65:1162-1165, Novack,J.C.,et al., 2008

Multiple Sclerosis
Lancet 372:1502-1517, Compston,A. &Coles,A., 2008

What Are the Prospects of Stem Cell Therapy for Neurology?
BMJ 337:1325-1327, Chandran,S., 2008

Mitoxantrone for Multiple Sclerosis Causing Acute Lymphoblastic Leukemia
Neurol 68:1630-1631, Cartwright,M.S.,et al, 2007

How Effective Are Disease-Modifying Drugs in Delaying Progression in Relapsing-Onset MS?
Neurol 69:1498-1507, Brown,M.G.,et al, 2007

Diagnosis and Treatment of Multiple Sclerosis
BMJ 332:525-527, Murray,T.J., 2006

Effect of Mitoxantrone on MRI in Progressive MS, Results of the MIMS Trial
Neurol 65:690-695, Krapf,H.,et al, 2005

Changes in the Ascertainment of Multiple Sclerosis
Neurol 65:1066-1070, Marrie,R.A.,et al, 2005

Intravenous Immunoglobulin in Autoimmune Neuromuscular Diseases
JAMA 291:2367-2375, Dalakas,M.C., 2004

Intravenous Immunoglobulin in Secondary Progressive Multiple Sclerosis: Randomised Placebo-Controlled Trial
Lancet 364:1149-1156, Hommes,O.R.,et al, 2004

Interferon beta-1b in Secondary Progressive MS
Neurol 63:1779-1787,1768, Kappos,L.,et al, 2004

Interferon beta-1b in Secondary Progressive MS
Neurol 63:1788-1795,1768, The North American Study Group on Interferon beta-, 2004

Mitoxantrone for Multiple Sclerosis in Clinical Practice
Neurol 63(Suppl 6):S25-S27, Rizvi,S.A.,et al, 2004

Mitoxantrone Treatment of Multiple Sclerosis
Neurol 63(Suppl 6):S28-S32, Cohen,B.A. &Mikol,D.D., 2004

The Use of Mitoxantrone (Novantrone) for the Treatment of Multiple Sclerosis
Neurol 61:1332-1338, Goodin,D.S.,et al, 2003

Application of the New McDonald Criteria to Patients with Clinically Isolated Syndromes Suggestive of Mulitple Sclerosis
Ann Neurol 52:47-53, Dalton,C.M.,et al, 2002

Interferon Beta but not Glatiramer Acetate Therapy Aggravates Headaches in MS
Neurol 59:636-639, Pollmann,W.,et al, 2002

Benefit of Interferon B-1a on MSFC Progression in Secondary Progressive MS
Neurol 59:679-687, Cohen,J.A.,et al, 2002

Therapy-Related Acute Myeloblastic Leukemia After Mitoxantrone Treatment in a Patient with MS
Neurol 59:954-955, Brassat,D.,et al, 2002

Mitoxantrone in Progressive Multiple Sclerosis: A Placebo-Controlled, Double-Blind, Randomised, Multicentre Trial
Lancet 360:2018-2025, Hartung,H.,et al, 2002

Disease-Modifying Therapy in Multiple Sclerosis: Strategies for Optimizing Management
The Neurologist 8:227-236, Frohman,E.,et al, 2002

Randomized Controlled Trial of Interferon-beta-1a in Secondary Progressive MS
Neurol 56:1496-1504, Secondary Progressive Efficacy Clinical Trial of R, 2001

Randomized Controlled Trial of Interferon-beta-1a in Secondary Progressive MS
Neurol 56:1505-1513, Li,D.K.B.,et al, 2001

The Effect of IFNB-1b on the Evolution of Enhancing Lesions in Secondary Progressive MS
Neurol 57:2185-2190, Brex,P.A.,et al, 2001

Relapses and Progression of Disability in Multiple Sclerosis
NEJM 343:1430-1438,1486, Confavreux,C.,et al, 2000

Population Based Cost Utility Study of Interferon Beta-1b in Secondary Progressive Multiple Sclerosis
BMJ 319:1529-1533, Forbes,R.B.,et al, 1999

Use of Corticosteroids in Multiple Sclerosis by Consultant Neurologists in the United Kingdom
JNNP 54:362-365, Tremlett,H.L.,et al, 1998

Placebo-Controlled Multicentre Randomised Trial of Interferon B-1b in Treatment of Secondary Progressive Multiple Sclerosis
Lancet 352:1491-1497,1486, European Study Group on Interferon B-1b in Seconda, 1998

Management of Multiple Sclerosis
NEJM 337:1604-1611, Rudick,R.A.,et al, 1997

Low-Dose Oral Methotrexate in Chronic Progressive Multiple Sclerosis:Analyses of Serial MRIs
Neurol 47:1153-1157, Goodkin,D.E.,et al, 1996

Low-Dose (7. 5mg) Oral Methotrexate Reduces the Rate of Progression in Chronic Progressive Multiple Sclerosis
Ann Nuerol 37:30-40, 51995., Goodkin,D.E.,et al, 1995

Are Magnetic Resonance Findings Pred of Clinical Outcome in Therapeutic Trials in MS? The Dilemma of Interferon-B
Ann Neurol 36:14-18, McDonald,W.I.,et al, 1994

Cladribine in Treatment of Chronic Progressive Multiple Sclerosis
Lancet 344:3-13, Sipe,J.C.,et al, 1994

Oral Megadose Methylprednisolone Therapy in a Pt with Chronic Progressive MS
Neurol 43:230, Gucuyener,K.,et al, 1993

Intermittent Cyclophosphamide Pulse Therapy in Progressive MS:NE Coop MS Trtm Grp
Neurol 43:910-918, Weiner,H.L.,et al, 1993

The Canadian Coop Trial of Cyclophosphamide and Plasma Exchange in Progr MS
The Canadian Coop MS Study Group, Lancet 337:441-4461991., , 1991

Plasma Exchange in Chronic Progressive Multiple Sclerosis:A Long-Term Study
Neurol 41:409-414, Khatri,B.O.,et al, 1991

A Placebo-Controlled, Double-Blind, Randomized, Two-Center, Pilot Trial of Cop 1 in Chronic Progressive MS
Neurol 41:533-539, Bornstein,M.B.,et al, 1991



Showing articles 0 to 50 of 55 Next >>